It is important to note that 88% of MDS patients clusterized according to the above-mentioned criteria, excluding blast cell number, have bone marrow blasts <5%; the remaining 12% have blood number >5%, but were shifted in other clusters, such as in the cluster characterized by TP53 mutations [15]. The gene discussed is TP53; the disease is myelodysplastic syndrome.